|
|
|
市場調查報告書
全球的癌治療市場
Cancer Therapies
|
全球的癌治療市場 是由出版商Global Industry Analysts, Inc.在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 897 價格從美金4500起跳。
本報告書內容包括:全球的癌治療市場的分析、美國、日本、歐洲的各分類市場趨勢、2009∼2017年的預測、市場所加入的企業152家的介紹等彙整、內容綱要摘記如下:
第1章 介紹・調查方法・產品定義
第2章 業界概要
- 癌治療：今後的展望
- 美國獨佔全球市場
- 免疫療法為主導的標的療法為焦點
- 癌治療：展望
- 主要藥劑廠商的成功在癌市場的關心為高度的領域
- 單株抗體開啟癌治療市場的新時代
- 生物療法促進癌治療市場的成長
- 癌治療藥：全球的醫藥品生產線主導
- 新的癌治療會有登場的趨勢
- 美國先主導癌治療藥的認定
- 癌治療的競爭刺激化
- 癌的生物療法領域的競争刺激化
第3章 趨勢和課題
- 癌的給藥技術創新：產品差別化的主要因素
- 後續藥劑的適應擴大癌生產線
- 個別化醫療
- 併用用療法
- 品牌藥的專利失效為非專利藥的競争
- 藥劑廠商的新問題所帶來的投資擴大
- 癌藥劑開發的新課題
- 主要藥劑在2010年接受FDA的回覆
- 藥劑的失敗：新的治療法的黑暗展望
- 2010年癌治療藥第3階段臨床試驗的失敗
- 藥劑撤退對製藥公司的影響
第4章 市場促進因素和阻礙因素
- 成長促進因素
- 癌發病率的提升和現代的治療法的連結促進成長
- 人口統計、生活習慣提升癌的風險
- 尚未被滿足的需求促進更上一層的研究開發
- 癌研究的加入障礙降低促進劃時代的開發
- 國家的醫療當局之投資擴大
- 效率和價格的提升招惹製造業者
- 補足癌治療藥貢獻其成長
- 健檢、診斷的改善、患者的生存率
- 分子影像技術
- 技術創新、改善、認定
- 成長阻礙因素
- 標的療法的價格提升阻礙發展速度
- 腫瘤的特異性和毒性
- 複雜的治療通訊協定
- 吸菸率的降低
- 複合的藥劑耐性
- 法律規範的嚴苛阻礙市場認定
- 臨床試驗的課題
- 高度開發費帶領製造業者前往發展中國家
第5章 標的療法
第6章 免疫療法
第7章 賀爾蒙療法
第8章 化學療法
第9章 癌的概要
第10章 全球的癌統計
第11章 藥劑認定和臨床試驗
第12章 新藥開發和上市
第13章 近年的業界活動
第14章 主要企業
第15章 全球市場展望
第16章 美國市場
第17章 日本市場
第18章 歐洲市場
第19章 其他各國
Abstract
This report analyzes the worldwide markets for Cancer Therapies in US$ Million by the following Product Segments: Immunotherapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 152 companies including many key and niche players such as Amgen, Inc., AstraZeneca PLC, Bayer Schering Pharma, Biogen Idec Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, Imclone Systems, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Genzyme, GlaxoSmithKline, Janssen Biotech, Inc., Merck KGaA, Novartis AG, OSI Pharmaceuticals, Inc., Pfizer, Sanofi-Aventis, Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Immunotherapy
- Targeted Therapy
- Hormonal Therapy
- Chemotherapy
2. INDUSTRY OVERVIEW
- Cancer Therapies: An Outlook
- US Retains Global Dominance
- Immunotherapies Lead the Suite, Targeted Therapies to Claim the Top Spot
- Cancer Therapies: A Review
- Enduring Success of Top Drug Makers Makes Oncology Area More Endearing
- Table 1: Select Leading Cancer Therapies Worldwide by Revenues: 2006-2010 (includes corresponding Graph/Chart)
- Monoclonal Antibodies Open Up a New Era in Cancer Treatment
- Table 2: Leading Monoclonal Antibodies Worldwide by Revenues: 2009 & 2010
- Biotherapies to Drive Growth in Cancer Therapy Market
- Biotech Cancer Therapies Yet to Overcome Teething Issues
- Oncology Drugs - the Leader in the Global Pharma Pipeline
- Table 3: Cancer Therapies Market: Number of Approved/Marketed and Pipeline Drugs by Select Cancer Types as of 2010 (includes corresponding Graph/Chart)
- New Cancer Therapies Appear Over the Horizon
- Late Stage Promising Drugs in Cancer Therapy
- US Ahead in Approving Cancer Drugs
- FDA-Approved Oncology Drugs in Recent Years (2008-2011)
- New Cancer Drugs Approved by EMA in 2009 and 2010
- Competition Set to Rise in Cancer Therapy
- Table 4: Leading Companies in the Global Oncology Therapy Market (2010): Percentage Breakdown of Revenues for Roche, Novartis, Amgen, AstraZeneca, sanofi-aventis and Celgene (includes corresponding Graph/Chart)
- Competition Intensifies in the Cancer Biotherapy Segment
3. TRENDS AND ISSUES
- Innovations in Cancer Drug Delivery: A Key Factor in Product Differentiation
- Follow-On Indications Flock Oncology Pipeline
- Personalized Medicine: Gain in Importance
- Combination Therapy: A Double Whammy Success
- Patent Expiries of Branded Drugs to Trigger Generic Competition
- Rising Investments Bring in New Troubles for Drug Makers
- Emerging Challenges in Cancer Drug Development
- Select Drugs Receiving Complete Response Letters from the FDA in 2010
- Drug Failures - Deterring Prospects of New Therapies
- Failures in Phase III Clinical Trials of Oncology Drugs in 2010
- Drug Withdrawals Hurt Pharma Companies
4. MARKET DRIVERS AND RESTRAINTS
- Growth Drivers In a Capsule
- Rise in Cancer Incidences & Access to Modern Therapeutics Foster Growth
- Demographics & Lifestyles Raise the Risk of Cancer
- Cancer Prone Sites based on Age
- Table 5: Population of People Aged More than 65 Years in United States for the years 2000, 2010, and 2020 (includes corresponding Graph/Chart)
- Unmet Needs Leave Scope for Further Research and Development
- Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
- Increasing Investments by National Health Authorities
- Efficiency & High Prices Magnetize Manufacturers
- Supportive Cancer Drugs Contribute to Growth
- Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
- Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
- Innovations, Improvements, and Approvals Propel Growth
- Growth Restraints
- High Prices of Targeted Therapies Act as a Speed Breaker
- Table 6: Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2008
- Limited Tumor Specificity and Toxicity
- Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
- Reduced Smoking
- Reimbursement and Coverage Remains a Major Challenge
- Changes in Reimbursement Policies Influence Market Prospects
- Multiple Drug Resistance
- Stringent Regulations Delay Market Approval
- Challenges Encountered in Clinical Trials
- High Development Costs Retracts Manufacturers in Developing Countries
5. TARGETED THERAPEUTICS
- Current and Future Analysis
- Targeted Therapy - An Overview
- Targeted Therapy: The New Frontier of Cancer Treatment
- List of Select Approved Targeted Therapy Drugs by Indication
- Select Targeted Anti-Cancer Therapies in Late-Stage (Phase III) Clinical Development
- Table 7: Targeted Therapies Market Worldwide (2010): Percentage Breakdown of Targeted Therapeutic Drugs under Various Stages of Development (includes corresponding Graph/Chart)
- Table 8: Molecular Targeted Therapies Worldwide: Percentage Breakdown of Molecular Targeted Therapies under Pipeline by Drug Class as of 2010 (includes corresponding Graph/Chart)
- Types of Targeted Therapy
- Tyrosine Kinase Inhibitors
- List of Approved Tyrosine Kinase Inhibitors
- Angiogenesis Inhibitors
- List of Approved Angiogenesis Inhibitors
- Proteasome Inhibitors
- Multi-Targeted Drugs
- Select Approved Multi-Targeted Drugs in Targeted Cancer Therapy
- Gene Therapy
6. IMMUNOTHERAPY
- Current and Future Analysis
- Table 9: Global Market for Immunotherapy (2007 and 2012): Percentage Breakdown of Revenues by Drug Class - Monoclonal Antibodies, Biological Response Modifiers, Vaccines, and Other Immunotherapy Products (includes corresponding Graph/Chart)
- Immunotherapy Treatment Strategies
- Vaccination with Dendritic Cells Pulsed With Tumor Antigens
- Gene Technique-Based Immunotherapy
- Inhibiting Tumor-Induced Immunosuppression
- Immunostimulants
- Use of Monoclonal Antibodies
- Immunotoxins
- Radioimmunotherapy
- T Cells based Therapy
- Types of Cancer Immunotherapy Drugs
- Monoclonal Antibodies
- Select Immunotherapy-based Monoclonal Antibodies Approved for Cancer Treatment
- Vaccines - A Promising Future Area of Cancer Therapeutics
- Therapeutic Cancer Vaccines: Harnessing the Immune System to Fight Cancer
- Cancer Vaccine Strategies
- RNA-Loaded Dendritic Cells Cancer Vaccine:
- Liposomal Vaccine:
- Vaccine Targeting Pregnancy Hormone:
- Viral Vector Vaccine:
- Listeria-Based Vaccine:
- Telomerase Targeting Vaccine:
- Cancer Vaccine Makes Debut in the US, Finally
- Approved Therapeutic Cancer Vaccines Worldwide
- Cancer Vaccine Pipeline Shows Significant Promise
- World Cancer Vaccine Pipeline as of 2011
- Long-Drawn Journey to Success Offers New Lessons for Drug Makers
7. HORMONE THERAPY
- Current and Future Analysis
- Hormonal Therapy - An Overview
- Hormonal Therapy Strategies
- Hormone Synthesis Inhibitors
- Aromatase Inhibitors
- GnRH Analogs
- Hormone Receptor Antagonists
- Selective Estrogen Receptor Modulators (SERMs)
- Antiandrogens
- Hormone Supplementation
- Progestagens and Androgens
- Estrogens
- Somatostatin Analogs
- Shifting Therapeutic Preferences
- Table 10: Global Market for Antihormonal Therapy (2005 and 2014): Percentage Breakdown of Revenues by Drug Class - LHRH Analogs, Aromatase Inhibitors, Anti-androgens, Anti-estrogens, and Other Hormone Antagonists (includes corresponding Graph/Chart)
- Drug Classes in Hormone Therapy
- Drugs Used in Hormone Therapy and Their Uses
- Side-Effects Associated with the Use of Various Drugs in Hormone Therapy
8. CHEMOTHERAPY
- Current and Future Analysis
- Chemotherapy - An Overview
- The Chemotherapy Market Space - An Overview
- Chemotherapy Market Cluttered with Numerous Players
- Chemotherapy Drugs Require Careful Handling
- Types of Chemotherapy
- Adjuvant Chemotherapy
- Combined Modality Chemotherapy
- Neoadjuvant Chemotherapy
- Palliative Chemotherapy
- Chemotherapy Drug Classes
- Nucleoside Analogues
- Alkylating Agents
- Antimetabolites
- Nitrosoureas
- Steroid hormones
- Platinum Containing Compounds
- Folate antagonists
- Microtubule-targeting agents
- Topoisomerase inhibitors
- Risks Associated with Chemotherapy
- When Chemotherapy Fails...
9. AN OVERVIEW OF CANCERS
- Cancer: A Major Health Crisis in the Modern World
- Table 11: Cancer Causes in Developed and Developing Countries (2010): Percentage Breakdown by Risk Factors - Diet or Nutrition, Infections, Tobacco, and Other Factors (includes corresponding Graph/Chart)
- Types of Cancers
- Prostate Cancer
- Select FDA-Approved Prostate Cancer Drugs
- Select Prostate Cancer Agents in Mid- & Late-Stage Clinical Development
- Table 12: Revenues of Select Leading Prostate Cancer Drugs: 2006-2010 (includes corresponding Graph/Chart)
- Breast Cancer
- Select FDA Approved Breast Cancer Drugs
- Table 13: Breast Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)
- Cervical Cancer
- Colorectal Cancer
- Select FDA-Approved Colorectal Cancer Drugs
- Table 14: Colorectal Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)
- Lung Cancer
- Select FDA-Approved Non-Small Cell Lung Cancer Drugs
- Table 15: Lung Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)
- Renal Cancer
- Select FDA-Approved Renal Cell Carcinoma Drugs
- Skin Cancer
- Table 16: Skin Cancer/Melanoma Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)
- Pancreatic Cancer
- Table 17: Pancreatic Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)
- Non-Hodgkin's Lymphoma
- Leukemia
- Bladder Cancer
- Table 18: Bladder Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)
- Endometrial Cancer
10. WORLD CANCER STATISTICS
- Cancer Incidence - Statistics on New Cases
- Table 19: Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart)
- Table 20: Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart)
- Table 21: Cancer Incidence in Upper Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart)
- Table 22: Cancer Incidence in Lower Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart)
- Table 23: Cancer Incidence in High Income Countries by Site: 2009 (includes corresponding Graph/Chart)
11. DRUG APPROVALS AND CLINICAL TRIALS
- Merck Receives Approval for EMEND(r) IV in Canada
- Sun Pharma Receives FDA Approval for Docefrez
- Amgen Secures FDA Approval for Denosumab
- Eisai Receives FDA Approval for Halaven
- Dendreon Corporation Secures FDA Approval for Provenge
- GlaxoSmithKline Secures Accelerated Approval from FDA for TYKERB
- Roche Receives European Commission Approval for Herceptin in Metastatic Gastric Cancer Treatment
- Gloucester Pharmaceuticals Receives FDA Approval for Istodax
- YM BioSciences Gains Marketing Approval for Nimotuzumab in Mexico
- Bristol-Myers and ImClone Receives FDA Approval for Erbitux Labeling Revisions
- Abraxis Receives Approval for Abraxane in Quebec, Canada
- Genentech Receives FDA Approval for Avastin
- ABRAXANE Gains Marketing Approval in Korea, Australia and Other Countries
- GlaxoSmithKline's Cervarix Finds Place in UK National Immunization Programme
- Biogen Idec and Elan Commence Clinical Trial of TYSABRI
- Calistoga Pharmaceuticals Starts Phase I Clinical Trial of CAL-101
- Progen Pharmaceuticals Continues Phase 1 Development of PG-11047
- GlaxoSmithKline Receives Conditional EU Approval for Marketing Lapatinib
- Roche's Xeloda Gains EU Approval for Use in Colorectal Cancer Treatment
- Genentech Secures FDA Approval for Avastin
- EU Approves Four Biosimilar Versions of Neupogen
- Russia Approves Oncophage for Kidney Cancer Treatment
- Eisai to Start Clinical Testing of MORAb-028
- Threshold Pharmaceuticals Starts Phase I/II Clinical Trials of TH-302
- AVEO Commences Phase 1b Clinical Study of AV-951 and FOLFOX6
- GSK's Tykerb Receives USFDA Approval
- Seattle Genetics Initiates Phase 1b Clinical Trials of SGN-40 with Gemzar and Rituxan
- S*Bio Initiates Phase I Clinical Trials of SB1518
- Merck Serono Initiates Phase III Trials of Cladribine
- BioCurex Receives Patent for RECAF Technology Applications
- Chidamide/HBI-8000 Completes Phase I Clinical Trials in China
- AVEO Initiates Phase I Trials of AV 299
- Exelixis Completes Phase I Trials of XL765
- Infinity Pharmaceuticals Starts Phase I Clinical Trial of IPI-926
- Cell Genesys Terminates its VITAL-1 Phase 3 Trial of GVAX
- GTx Completes Phase II Clinical Trials of Ostarine
- Imclone Awaits Approval for Erbitux from US Medicine Regulator
- Kuhnil and Daiichi Sankyo Initiate Phase II Clinical Trial of Nimotuzumab
- Peplin Starts Phase III Clinical Trials of PEP005 Gel
- ERBITUX Receives Marketing Approval in Japan
- Progenics Starts Phase I Clinical Study of PSMA ADC
- FDA Awards Orphan Drug Designation for the Use of Stem Cell Technology in Bone Marrow Transplantations
- Roche, OSI and Chugai Receive Approval for Tarceva in Japan
- Eisai Receives FDA Approval for ONTAK(r)
- Genmab Terminates the Development of HuMax-CD4
- Teva Pharmaceutical Acquires EU Authorization to Market Neutropenia Drug
- Novartis' Everolimus Awaits Approvals from US FDA, Swissmedic, and EMEA
- Abraxis BioScience, AstraZeneca, and NCCN to Conduct Anti-cancer Drug Studies
- Sanofi-Aventis Receives Japanese Approval for Taxotere(r) Injection
- Roche's Avastin Bags European Approval for Renal Cancer Treatment
- Roche Announces European Approval of Herceptin
- GSK's Hycamtin Obtains FDA Approval
- Avastin Receives European Approval for Breast Cancer Treatment
- Roche's Tarceva Obtains European Approval
- Roche's NeoRecormon Gains European Approval
- Northwest Biotherapeutics' DCVax-Brain Gains Swiss Approval
- Alfacell's ONCONASE Receives Orphan Drug Designation from US
- Cougar Biotechnology Commences Phase II Trial of CB7630
- Lorus Therapeutics Receives Orphan Drug Designation for its LOR-2040
- Merck Serono Receives EU Approval for mCRC Treatment With Erbitux
- MGI PHARMA and HELSINN Receive FDA Approval For Aloxi
- FDA Grants Approval for Sutent, a Kidney and Gastrointestinal Cancer Drug
- Wyeth Pharmaceuticals' TORISEL Receives FDA Approval
- Dabur Pharma Acquires FDA Approval for Paclitaxel Injection
- EUSA's CAPHOSOL Finds Application in Treating Oral Mucositis
- European Commission Approves Amgen's Vectibix for Metastatic Colorectal Cancer
- GPC Biotech Starts Phase 2 Trials of Satraplatin plus with Tarceva
- FDA Approves Vectibix as Treatment for Metastatic Colorectal Cancer
- FDA Approves IND Indication for CYT-500 of Cytogen
- FDA Clears Rituxan for New Indications
- Epeius Receives BFAD Approval for Expanded Access Program for Rexin- G
- BioMedicines Initiates Phase 1b Study of Biomed 101
- Avastin Obtains FDA Approval for Treating Recurrent Colorectal Cancer
- Genentech's Herceptin Gains FDA Nod for Treating Early stage Cancer after Surgery
- Epeius Starts Phase I and II Trials of the New Tri-Rex Vaccination Protocol
- Sonus Begins Phase 1 Clinical Trial of TOCOSOL(r) Camptothecin
- Dynavax Begins Phase 1 Clinical Trial of TLR9 agonist Combined with Chemotherapy Regimen
- Morphotek's MORAb-009 Receives Orphan Drug Designation
- Morphotek's MORAb-003 Receives Orphan Drug Status from the US FDA
- Morphotek Grants FDA Approval of the IND for MORAb-009
- MannKind Receives IND Clearance for MKC1106-PP Immunotherapy
- Pharmexa Initiates Phase II trials of GV 1001
- Wyeth Pharmaceuticals Declares Discontinuation of Phase III Clinical Trials for Temsirolimus
- OXiGENE Announces Clinical Trials of CA4P
- Glaxo SmithKline's Hycamtin Gains FDA Approval for Treating Cervical Cancer
- Cell Genesys Announces the Initiation of Amplified Phase I Trial of CG0070
- Genentech's Avastin Receives FDA Approval for Lung Cancer Treatment
- Vorinostat Acquires FDA Approval for Skin Cancer Treatment
- Callisto Launches the First Clinical Trial of Landmark Discovery, L-Annamycin for ALL
- Shanghai Sunway Biotech's H101 Receives Marketing Approval in China
- Northwest Biotherapeutics Gains Patent for CXCR4
- Biocon's Cancer Drug Initiates Phase II Trials
12. NEW DRUG DEVELOPMENTS AND LAUNCHES
- Dr Reddy's Laboratories Introduces Peg-Grafeel Injection in India
- Sanofi-Aventis Introduces Jevtana (cabazitaxel) Injection in the US
- Natco Pharma Introduces Anastrazole for Breast Cancer in US
- Dr Reddy's Laboratories Introduces Anastrazole Tablets in US
- Zynx Health Introduces Zynx OncologyCare
- Ferring Pharmaceuticals Introduces FIRMAGON(r) in Europe
- GSK Launches Cervarix in Singapore
- Abeome Launches New Stem Cell Monoclonal Antibody
- Dabur Pharma Launches a New Drug Delivery System, Nanoxel
- Epeius Biotechnologies Develops New Targeted Anti-Cancer Drugs
- Monash University Scientists Develop siRNA for Cancer Treatment
- Cytogen Introduces SOLTAMOX(tm), the First Hormonal Breast Cancer Therapy
13. RECENT INDUSTRY ACTIVITY
- BioLineRx Acquires License Rights of BL-7030 from Algen
- Glenmark Establishes New Manufacturing Plant in Argentina
- Centella Therapeutics Signs Licensing Agreement with Auckland UniServices
- Cephalon Enters a Definitive Merger Agreement with Gemin X
- IRX Therapeutics Enters a New Research Collaboration
- RXi Pharmaceuticals Acquires Apthera
- Gilead Sciences to Enter into Collaboration with Yale School of Medicine for Cancer Therapies
- Sage Bionetworks Forms Alliance with AstraZeneca
- Amgen Acquires BioVex Group
- AREVA Inks Cooperative Research Agreement with INSERM
- Dendreon Secures FDA Approval for New Jersey Manufacturing Facility
- Celgene Acquires Abraxis BioScience
- HUYA Partners with Quintiles to Co-Develop HBI-8000 Cancer drug (US/China)
- China PharmaHub Signs Agreement with Global Player in Precision Glass Technology
- Immunotope Partners with Midatech Group to Form Syntara
- ChromoCure Acquires GRG
- Qatar National Cancer Society and SAH Global Sign MoU
- Neogenix Gains FDA Orphan Drug Designation for Ensituximab
- ImmunoGen Gains Orphan Drug Status for Lorvotuzumab Mertansine
- Syngene International Enters Into Agreement with Endo Pharmaceuticals
- Immunovaccine and Oncothyreon Ink Research Agreement
- OncoGenex Inks Licensing Agreement with Teva Pharmaceutical
- NanoCarrier Enter into Comprehensive Joint Research Agreement with MEDINET
- VaxOnco Acquires Intellectual Property Rights for Onyvax-P
- Novation Pharmaceuticals and Cancer Therapeutics Enter into Collaboration
- Cancer Therapeutics Signs Letter of Intent with NanoTherapies
- sanofi-aventis Acquires BiPar Sciences
- IBt Bebig, Rusnanotech and Santis Form Joint Venture for Cancer Treatment
- Roche Acquires Genentech
- AstraZeneca Enters into Collaboration with Merck
- Cytopia Merges with YM BioSciences
- Aveo Pharmaceuticals and Biogen Idec Sign Definitive Agreement
- Opsona Therapeutics Inks Research and Collaboration Agreement with CSL
- Micromet Signs Agreement with Lonza
- Clavis Pharma Enters Into Agreement with Clovis Oncology
- Abraxis Takes Over Platco and Shimoda
- WEHI Collaborates with Abbott and Genentech
- Novartis Inks a Production Deal with Lonza
- Roche Takes Over UK-Based Biotech Company, Piramed
- Pfizer Acquires Encysive
- Eden Biodesign Inks a Marketing Services Deal with Human Genome Sciences
- FivePrime Join Hands with Pfizer for Cancer and Diabetes Research
- Sanofi-Aventis and Dyax Ink Two Antibody Pacts
- Pfizer and AVANT Ink a Global Licensing Agreement for CDX-110
- Takeda Inks an Exclusive Partnership Agreement with Amgen
- Genentech and Roche Ink a Licensing Agreement with Glycart
- Bristol-Myers Squibb Acquires Kosan Biosciences
- Nabi Biopharmaceuticals Collaborates with NIAID
- Pfizer to Acquire Serenex
- Morphotek Signs an Agreement with Pivotal BioSciences
- GE Healthcare Inks a Three-Year Agreement with Eli Lilly
- ArQule Signs Two Agreements with Daiichi Sankyo
- Circadian Completely Acquires Vegenics Limited
- Lpath Inks an Accord with Merck Serono
- Topex Expands its Distribution Deal with Therapy Remarketing
- Unibioscreen Inks a Partnership Agreement with Drais Pharmaceuticals
- Avant Immunotherapeutics Becomes Celldex Therapeutics
- Abraxis Enters into Definitive License Agreements with ProMetic Life Sciences
- Biovest International to Receive US$1.6 Million Funding for Biomedical Research
- Access Completes the Acquisition of Somanta
- Clinical Data Inks an Agreement to Take Over Avalon Pharmaceuticals
- EUSA Pharma Acquires Cytogen Corporation
- Oncologic Merges with Triton BioSystems
- Eli Lilly Takes Over ImClone Systems
- CEL-SCI Establishes a New Manufacturing Unit
- ZaBeCor Establishes Biothorpe Pharmaceuticals, a New Subsidiary
- Takara Bio Signs a Research Agreement with a Chinese University
- Shanghai Roche Expands its MabThera Marketing Activities
- Merck Completes the Acquisition of Majority Stake in Serono
- Merck Enters into Licensing and Collaboration Agreement With Idera
- Sanofi-Aventis Inks a Global Licensing Deal with Oxford BioMedica
- WEHI to Collaborate with Genentech and Roche
- AstraZeneca Acquires MedImmune
- Antisoma Enters into a Global Accord with Novartis
- Sanofi-Aventis and Astellas Pharma to Restructure their JV Operations in Japan
- Biomira Amends its Agreements with Merck
- AstraZeneca Takes Over Canadian Biologics Plant
- Pfizer Acquires Coley Pharmaceutical Group
- Abraxis Takes Over Watson's Manufacturing Facility
- Abraxis Takes Over Pfizer's Cruce Davila Manufacturing Facility
- Bristol-Myers Squibb Takes Over Adnexus Therapeutics
- Merck Partners with a Florida-based Research Center
- Organon Partners with Medarex
- Genzyme Acquires Bioenvision
- Genentech Inks a Deal with Seattle Genetics
- TopoTarget Takes Over Apoxis
- Roche Acquires CuraGen's Subsidiary
- GPC Biotech Inks an Agreement with Yakult
- MediGene Acquires Avidex
- Sanofi-Aventis Inks an Agreement with Taiho
- Biogen Inks Merger Agreement with Conforma
- Roche Signs a Merger Agreement with Ventana
- Roche Takes Over THP to Enhance Its Therapeutic Antibody Profile
- ImClone Systems and Merck Revise ERBITUX Agreement
- GSK Invests €500 Million in France
- Amgen Takes Over Avidia
- Moores Cancer Center Collaborates with Medarex
- ADITUS Medical Forms an Alliance with IGEA
- Callisto Opens Site For Phase-II Clinical Trials of Atiprimod
- XOMA Inks an Agreement with Attenuon
- AstraZeneca Joins Schering to Develop a Novel Breast Cancer Drug
- Nventa to Procure Hiltonol from Oncovir Incorporated
- MaxCyte and Medinet Sign an Agreement for Immuno- Cell Therapy
- Receptor Acquires Cancer Vaccine 'G17DT' from Aphton
- Enzon Collaborates with Santaris for Joint Development of Novel RNA Antagonists
- Epeius Receives Funding from Lazarex for Rexin-G(tm) Trials
- Callisto Inks a Deal with M.D. Anderson Cancer Center
- AstraZeneca Inks an Agreement with Abraxis BioScience
- diaDexus and BVF Establish CFD Therapeutics
- Merck Acquires US Rights for Liposome Vaccine
- Genentech Enters Into Alliance with Inotek
- AstraZeneca Takes Over KuDOS Pharmaceuticals
- Genzyme Acquires AnorMED
- Genentech Collaborates with Accelerate Brain Cancer Cure
- Sonus and Schering Enter into a Global Licensing Agreement
- Abgenix Inks Merger Agreement with Amgen
- AstraZeneca and Astex Enter into an Alliance
- Pfizer Inks Global License Pact with Coley Pharmaceutical Group
- Genzyme Takes Over ILEX Oncology
- Genentech and CGI Enter into an Exclusive Agreement
14. FOCUS ON SELECT PLAYERS
- Amgen, Inc. (USA)
- Amgen's Oncology Pipeline As of 2011
- AstraZeneca PLC (UK)
- AstraZeneca's Cancer Drugs Under Pipeline as of 2011
- Bayer Schering Pharma (Germany)
- Bayer's Oncology Pipeline (As of 2011)
- Biogen Idec Inc (USA)
- Bristol-Myers Squibb Company (USA)
- Celgene Corporation (USA)
- Celgene's Oncology Drug Pipeline (As of 2011)
- Cell Therapeutics, Inc. (USA)
- Cell Therapeutics' Oncology Pipeline (As of 2011)
- Cephalon, Inc. (USA)
- Cephalon's Oncology Pipeline (As of 2011)
- Chugai Pharmaceutical Co., Ltd. (Japan)
- Chugai's Oncology Drug Pipeline (As of 2011)
- Eli Lilly and Company (USA)
- Lilly's Oncology Drug Pipeline as of 2011
- Imclone Systems, Inc (USA)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Select Mid- and Late- Stage Compounds in Roche's Oncology Pipeline
- Genentech, Inc. (USA)
- Genzyme (USA)
- Genzymes' Oncology Drug Pipeline as of 2011
- GlaxoSmithKline (UK)
- GlaxoSmithKline's Oncology Pipeline (As of 2011)
- Janssen Biotech, Inc (USA)
- Merck KGaA (Germany)
- Merck Serono's Oncology Pipeline (As of 2011)
- Novartis AG (Switzerland)
- Novartis' Oncology Drug Pipeline (As of 2011)
- OSI Pharmaceuticals, Inc. (USA)
- OSI Pharmaceuticals' Oncology Pipeline Status (As of 2011)
- Pfizer (USA)
- Pfizer's Oncology Drug Pipeline (As of 2011)
- Sanofi-Aventis (France)
- Oncology Drug Pipeline of sanofi-aventis as of 2011
- Seattle Genetics, Inc. (USA)
- Seattle's Cancer Therapy Pipeline as of 2011
- Takeda Pharmaceutical Company Limited (Japan)
- Takeda's Oncology Pipeline (As of 2011)
15. GLOBAL MARKET PERSPECTIVE
- Table 24: Global Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 25: Global Historic Review for Cancer Therapies by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 26: Global 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Analytics by Segment
- Table 27: Global Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 28: Global Historic Review for Immunotherapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 29: Global 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 30: Global Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 31: Global Historic Review for Targeted Therapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 32: Global 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 33: Global Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 34: Global Historic Review for Hormone Therapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 35: Global 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 36: Global Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 37: Global Historic Review for Chemotherapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 38: Global 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
16. THE UNITED STATES
- A. Market Analysis
- Current and Future Analysis
- Table 39: Sales of Select Leading Cancer Drugs in the US (2009 & 2010) (includes corresponding Graph/Chart)
- Recession Hits the Pharma Market, Oncology Area too Succumbs
- Medicare Restructures its Coverage for Chemotherapy
- Personalized Care for Cancer Treatment in US
- Drugs in Development in the US - A Recent Past Scenario
- Chemotherapy Drugs Undergoing Trials for Breast Cancer Treatment in United States (as of 2007)
- Hormonal Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United States (as of 2007)
- Targeted Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United States (as of 2007)
- Statistical Findings
- Table 40: US Market for Hospital Cancer Therapies (2004 and 2010): Percentage Breakdown of Revenues by Treatment Type - Surgery, Chemotherapy Drugs, Radiation Therapy, Biotechnology-Based Drugs, and Others (includes corresponding Graph/Chart)
- Table 41: US Demand for Chemotherapy Drugs (2004 and 2010): Percentage Breakdown of Revenues by Drug Class - Alkylating Agents & Related, Antimetabolites & Related, Mitotic Inhibitors, and Others (includes corresponding Graph/Chart)
- Table 42: US Market for Multiple Myeloma Therapeutics (2009): Percentage Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals and Others (includes corresponding Graph/Chart)
- Table 43: US Market for Breast Cancer Therapeutics (2010): Percentage Breakdown of Revenues by Segment: Targeted Therapeutics, Cytotoxic Therapeutics, and Hormonal Therapeutics, and (includes corresponding Graph/Chart)
- US Cancer Statistics
- Table 44: New Cancer Cases in the US by Affected Site: 2009 (includes corresponding Graph/Chart)
- Table 45: New Cancer Cases in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)
- Table 46: New Cancer Cases in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart)
- Cancer Mortality Statistics
- Table 47: Cancer Related Deaths in the US By Affected Site: 2009 (includes corresponding Graph/Chart)
- Table 48: Cancer Related Deaths in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)
- Table 49: Cancer Related Deaths in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart)
- New Drug Approvals
- New Drug Launches
- Strategic Corporate Developments
- Focus on Select Major Players
- B. Market Analytics
- Table 50: The US Recent Past, Current & Future Analysis for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 51: The US Historic Review for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 52: The US 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
17. JAPAN
- A. Market Analysis
- Current and Future Analysis
- Focus on Select Major Players
- B. Market Analytics
- Table 53: Japanese Recent Past, Current & Future Analysis for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 54: Japanese Historic Review for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 55: Japanese 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
18. EUROPE
- A. Market Analysis
- Current and Future Analysis
- Regional Perspective
- Advancements in Breast Cancer Treatment in Europe
- New Formulations that are Under Clinical Trials
- Drugs Undergoing Trials for Bladder Cancer Treatment in Europe As of 2006
- European Cancer Statistics
- Table 56: Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart)
- New Drug Approval
- New Drug Launch
- Strategic Corporate Developments
- Focus on Select Major Players
- B. Market Analytics
- Table 57: European Recent Past, Current & Future Analysis for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 58: European Historic Review for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 59: European 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
19. REST OF WORLD
- A. Market Analysis
- Current and Future Analysis
- Regional Market Overview
- Table 60: Estimated New Cancer Cases by Type/ Site Among Canadian Men: 2010 (includes corresponding Graph/Chart)
- Table 61: Estimated New Cancer Cases by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart)
- Table 62: Estimated Cancer Deaths by Type/Site Among Canadian Men: 2010 (includes corresponding Graph/Chart)
- Table 63: Estimated Cancer Deaths by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart)
- Asia
- Cancer Statistics in Asia-Pacific
- Table 64: Cancer Incidence in Asia-Oceania by Site: 2009 (includes corresponding Graph/Chart)
- Australia
- India
- Korea
- Malaysia
- Latin America
- Brazil
- Mexico
- Argentina
- New Drug Approvals
- New Drug Launches
- Strategic Corporate Developments
- B. Market Analytics
- Table 65: Rest of World Recent Past, Current & Future Analysis for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 66: Rest of World Historic Review for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 67: Rest of World 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
|
 |
